Masimo SET ® Is the Primary Pulse Oximetry at All 10 Top U.S. Hospitals, Monitors More Than 200 Million Patients a Year, and Has Been Shown to Have Unrivaled Accuracy and Reliability in More Than 100 ...
IRVINE, Calif.--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today the release of MX-7™, its latest and most advanced rainbow SET® board. Designed for integration into the more than 200 ...
CHICAGO & IRVINE, Calif.--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) and Masimo (Nasdaq: MASI) today announced a joint agreement to integrate Masimo Signal Extraction Technology® (SET®) pulse ...
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced Dual SET ® Pulse Oximetry for Root ®, a highly versatile patient monitoring and connectivity hub. The first application ...
The FDA clearance allows the W1 wearable to be sold for both over-the-counter and prescription use—making it the first SpO2-tracking smartwatch to carry both indications in the U.S., per Masimo.
These promising results—from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile patient population—add to previously published evidence of its strong ...